Lantheus (NASDAQ:LNTH) Issues FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 6.650-6.700 for the period, compared to the consensus EPS estimate of 6.750. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Lantheus Stock Up 0.8 %

LNTH opened at $98.31 on Tuesday. The stock has a market cap of $6.84 billion, a P/E ratio of 16.36 and a beta of 0.46. Lantheus has a 12 month low of $51.79 and a 12 month high of $126.89. The company has a fifty day simple moving average of $91.55 and a 200 day simple moving average of $100.35.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective on the stock. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Insider Transactions at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.